I am interested in Canadian and world Issues. I am COVID conscious and believe in climate change. I am a retired teacher who is most interested in the opinions of young people especially Gen Z.
Data Studio turns your data into informative dashboards and reports that are easy to read, easy to share, and fully customizable.
Covid in Canada right now is low as is the flu and RSV. I have noticed that there is not much coughing in public places. It would be great if things stayed like this for a while.
Report providing the latest information on Covid activity in the UK and other countries. This post is best viewed using the browser or Subst
You need to scroll down in this article to see the Canadian and US results.
Five years later, no matter how much researchers have learned since the original COVID-19 virus hit the U.S. in early 2020, there are still unknowns about the virus and its effects on the immune system. One puzzling connection is popping up between COVID and autoimmune conditions, including type 1 diabetes (T1D), according to new research from the University of Utah published in the journal ImmunoInformatics.
New research shows Covid vaccines may boost cancer treatment, helping the immune system fight tumors and nearly doubling patient survival co
New research shows Covid vaccines may boost cancer treatment, helping the immune system fight tumors and nearly doubling patient survival compared with those unvaccinated. https://theintellectualistofficial.substack.com/p/mrna-covid-vaccines-help-cancer-patients
Researchers at MD Anderson and the University of Florida found vaccinated lung and skin cancer patients lived nearly twice as long, suggesti
🚨 BREAKTHROUGH: MD Anderson Researchers dropped a cancer bomb
mRNA COVID vaccines + immunotherapy = 2x survival at 3 years.🧵
Patients who got an mRNA vaccine within 100 days of starting checkpoint inhibitors were TWICE as likely to be alive after 3 years vs. the unvaccinated.
The study examined nearly 3,800 cases in which the U.S. Occupational Safety and Health Administration (OSHA) confirmed that employees had co
The study examined nearly 3,800 cases in which the U.S. Occupational Safety and Health Administration (OSHA) confirmed that employees had contracted COVID-19 in connection with their work between 2020 and 2024. In total, 4,615 infected workers were identified in these investigations. Nearly two-thirds had died, and almost one-third required hospitalization.
The researchers found that the risk of exposure and infection was particularly high in health care and social assistance, public administration, and manufacturing. These occupations often involve close contact with other people or working in confined indoor environments where transmission can occur more easily.
The health care and social assistance sector alone accounted for nearly half of all OSHA investigations. Factory workers and others who work in close proximity to colleagues or the public were also overrepresented among those infected.
When the researchers compared the workforce with the general civilian population, they found that people in the labor force had about a 24% higher risk of dying from COVID-19 across the age groups studied. Men also had approximately a 15% higher risk of COVID-19-related death than women.
The researchers conclude that workplaces can play a major role in the spread of airborne infectious diseases. The findings show that workers in certain occupations face substantially higher risks than the general population and that stronger protective measures are needed to reduce illness, hospitalizations, and deaths during future pandemics.
The study is also a reminder that COVID-19 was not only an individual health issue but also an occupational hazard. The highest risks were observed in jobs where people could not work remotely and instead had to spend prolonged periods in close contact with patients, customers, clients, or coworkers.
This article is a perspective paper that focuses on a possible explanation for why many people with Long COVID develop chronic pain. The aut
This article is a perspective paper that focuses on a possible explanation for why many people with Long COVID develop chronic pain. The authors highlight growing evidence that autoantibodies—antibodies that mistakenly attack the body's own tissues—may play an important role.
Many people with Long COVID report symptoms such as burning skin pain, muscle pain, joint pain, nerve pain, increased sensitivity to pain, and discomfort from normal touch. These symptoms can persist for months or even years after the infection and are often difficult to explain using standard medical tests.
The researchers describe how SARS-CoV-2 infection may, in some individuals, trigger the immune system to produce autoantibodies. These autoantibodies may then affect nerves, blood vessels, and various receptors throughout the body. The result can be an overly sensitive nervous system that continues to generate pain signals even when no new injury is present.
The article compares these findings with other diseases in which autoantibodies are already known to cause pain and neurological symptoms. The authors argue that several observations in Long COVID resemble the mechanisms seen in such conditions.
The paper also discusses animal studies in which antibodies taken from people with Long COVID were transferred to laboratory animals. In some cases, the animals developed increased pain sensitivity, providing evidence that the antibodies themselves may contribute to symptoms rather than simply being an unrelated finding.
However, the authors emphasize that the evidence is not yet conclusive. It remains unclear exactly which autoantibodies are most important, why only some individuals develop them, and how much of Long COVID can actually be explained by this mechanism. Long COVID is likely driven by multiple biological processes, with autoantibodies representing only one part of the picture.
If this theory proves correct, it could have important implications for future treatments. Instead of focusing only on symptom relief, therapies could potentially target the harmful autoantibodies themselves or the immune processes that produce them. Similar approaches are already used in several autoimmune diseases.
